Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trebananib + Cisplatin/Capecitabine in Gastric/Esophageal Cancer
NCT00583674Phase 2Completed
- Sponsor
- Amgen
- Start
- Dec 2007
- Primary completion
- Mar 2010
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of trebananib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, distal esophageal adenocarcinoma, sponsored by Amgen. Started Dec 2007; status: completed.
02
Drugs
trebananib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomadistal esophageal adenocarcinoma
Beyond the preview
Go deeper on NCT00583674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00583674.